A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo

References

• Ahmed MS, Bae YS. (2014). Dendritic cell-based therapeutic cancer vaccines: past, present and future. Clin Exp Vaccine Res 3:113–16
   PubMedGoogle Scholar
• Alam MR, Ming X, Fisher M, et al. (2011). Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug Chem 22:1673–81
   PubMed Web of Science ®Google Scholar
• Anders HJ. (2004). Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15:854–67
   PubMed Web of Science ®Google Scholar
• Angart P, Vocelle D, Chan C, Walton S. (2013). Design of siRNA therapeutics from the molecular scale. Pharmaceuticals (Basel) 6:440–68
   PubMedGoogle Scholar
• Briat A, Wenk CHF, Ahmadi M, et al. (2012). Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single photon emission computed tomography and optical imaging. Cancer Sci 103:1105–10
   PubMed Web of Science ®Google Scholar
• Cetin B, Gumusay O, Cengiz M, Ozet A. (2016). Advances of molecular targeted therapy in gastric cancer. J Gastrointest Cancer 47:125–34
   PubMedGoogle Scholar
• Choi YJ, Lee DH, Choi CM, et al. (2015). Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naive non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. Bmc Cancer 15:763
   PubMed Web of Science ®Google Scholar
• Dahlman JE, Barnes C, Khan OF, et al. (2014). In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol 9:648–55
   PubMed Web of Science ®Google Scholar
• Dechantsreiter MA, Planker E, Matha B, et al. (1999). N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42:3033–40
   PubMed Web of Science ®Google Scholar
• Fehring V, Schaeper U, Ahrens K, et al. (2014). Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Mol Ther 22:811–20
   PubMed Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, et al. (2013). Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 119:421–75
   PubMed Web of Science ®Google Scholar
• Hamerski DA, Santoro SA. (1999). Integrins and the kidney: biology and pathobiology. Curr Opin Nephrol Hypertens 8:9–14
   PubMed Web of Science ®Google Scholar
• Horiike A, Yamamoto N, Tanaka H, et al. (2014). Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. Anticancer Res 34:1975–81
   PubMed Web of Science ®Google Scholar
• Hudis CA. (2007). Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39–51
   PubMed Web of Science ®Google Scholar
• Jonker DJ, Karapetis CS, Harbison C, et al. (2014). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer 110:648–55
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, Anderson D. (2013). Delivery materials for siRNA therapeutics. Nat Mater 12:967–77
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A, et al. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591–7
   PubMed Web of Science ®Google Scholar
• Knudsen KB, Northeved H, Kumar EK P, et al. (2015). In vivo toxicity of cationic micelles and liposomes. Nanomedicine 11:467–77
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord JP, Goncalves A, et al. (2015). Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–34
   PubMed Web of Science ®Google Scholar
• Lee SH, Kang YY, Jang H, et al. (2016). Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics. Adv Drug Deliv Rev 104:78–92
   PubMed Web of Science ®Google Scholar
• Li J, Xue S, Mao Z-W. (2016). Nanoparticle delivery systems for siRNA-based therapeutics. J Mater Chem B 4:6620–39
   PubMed Web of Science ®Google Scholar
• Liang JL, Ren XC, Lin Q. (2014). Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib. Onco Targets Ther 7:761–70
   PubMed Web of Science ®Google Scholar
• Liu L, Liu X, Xu Q, et al. (2014). Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy. Int J Nanomedicine 9:3509–26
   PubMed Web of Science ®Google Scholar
• Liu X, Wang W, Samarsky D, et al. (2014). Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res 42:11805–17
   PubMed Web of Science ®Google Scholar
• Louis DN. (2006). Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97–117
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–8
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Perrone F, Biondani P, et al. (2013). Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. Cancer Biol Ther 14:1098–103
   PubMed Web of Science ®Google Scholar
• Salic A, Mitchison TJ. (2008). A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 105:2415–20
   PubMed Web of Science ®Google Scholar
• Shen J, Kim H-C, Su H, et al. (2014). Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 4:487–97
   PubMed Web of Science ®Google Scholar
• Shen J, Xu R, Mai J, et al. (2013). High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano 7:9867–80
   PubMed Web of Science ®Google Scholar
• Shimaoka M, Xiao T, Liu JH, et al. (2003). Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 112:99–111
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang X, Zhang L, et al. (2015). Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release. Drug Deliv 22:389–99
   PubMed Web of Science ®Google Scholar
• Wang Y, Xiao W, Zhang Y, et al. (2016). Optimization of RGD-containing cyclic peptides against alphavbeta3 integrin. Mol Cancer Ther 15:232–40
   PubMed Web of Science ®Google Scholar
• Xu N, Fang W, Mu L, et al. (2016). Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget 7:3884–96
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu S, Qian L, et al. (2011). RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma. Eur J Pharm Biopharm 79:232–40
   PubMed Web of Science ®Google Scholar